Mitolactol

12/01/1982 - "Dibromodulcitol in the treatment of breast cancer."
11/01/1976 - "Evaluation of an intermittent schedule of dibromodulcitol in breast cancer."
12/01/1984 - "Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer."
12/01/1984 - "Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. "
10/01/1983 - "Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure."

01/01/1981 - "Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas."
08/01/1987 - "Dibromodulcitol treatment induced histological damages in solid Ehrlich carcinoma which increased on the effect of parallelly applied local fractionated X-irradiation. "
04/01/1984 - "Antitumor activity has been documented in this pilot study utilizing mitolactol in patients with advanced carcinoma of the cervix. "
01/01/1976 - "The effect of dibromodulcitol (Elobromolr, Mitolactolr, nsc 104 800) on the postoperative recurrences of the Guerin carcinoma of the rat."
09/01/1984 - "[Dibromodulcitol in combination with actinotherapy of spinocellular carcinoma]."

11/13/1994 - "[Pharmacokinetic study of dibromodulcitol in children with brain tumors]."
11/01/1990 - "Dibromodulcitol (DBD) is an anticancer agent that is cytotoxic against animal and human brain tumors in vivo. "
03/01/1997 - "To evaluate a combination of thioguanine, procarbazine, dibromodulcitol, CCNU (CCNU), fluorouracil, and hydroxyurea (TPDC-FuHu), designed to improve the efficacy of CCNU, in the treatment of recurrent metastatic brain tumors. "

01/01/1980 - "mammary carcinoma 1142A, Lewis lung carcinoma, metastatic model of the mammary carcinoma 1142A--a combined treatment consisting of vincristine--cyclophosphamide--metrotrexate--5-fluorouracil is superior to a combined treatment with carminomycin--dibromodulcitol. "

06/01/1985 - "Phase II study of mitolactol in advanced malignant melanoma."
01/01/1985 - "This study shows that mitolactol has moderate activity against advanced melanoma, and the drug deserves further study in combination with nonmyelotoxic drugs."
01/01/1985 - "The Central Pennsylvania Oncology Group conducted a phase II study of mitolactol in advanced metastatic melanoma to determine the overall survival rate and duration of response to this agent. "
01/01/1985 - "Phase II study of mitolactol in metastatic malignant melanoma."
10/01/1984 - "Twenty-four patients were evaluated in a non-randomized study to assess the effectiveness of dibromodulcitol (DBD) in Stage IV melanoma. "